Holen Sie sich die Stockscreener-App
155.12
2.74%
-4.4612
Schlusskurs vom Vortag:
$159.58
Offen:
$158.21
24-Stunden-Volumen:
221.98K
Relative Volume:
0.25
Marktkapitalisierung:
$7.64B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
19.37
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-0.38%
1M Leistung:
+3.62%
6M Leistung:
-4.79%
1J Leistung:
-24.06%
1-Tages-Spanne:
$155.13
$158.29
1-Wochen-Bereich:
$155.13
$160.00
52-Wochen-Spanne:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
155.18 | 7.73B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
484.68 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.07 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
634.23 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
117.37 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.72 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Stock Analysis | Charles River Laboratories International OutlookA Weak Technical Profile But Strong Fundamentals - AInvest
Pharmaceutical company to expand Charleston County operations - Live 5 News
Healthcare firms see growing activist investor involvement in the past year - Reuters
Charles River Labs scales back Memphis project, slashes expected jobs - The Business Journals
Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034 - GlobeNewswire Inc.
Earnings call transcript: Charles River Labs Q2 2025 beats EPS forecasts - Investing.com Canada
FRAUD AND MANIPULATION—1st Cir.: CEO’s reaction to macaque conspiracy was actionably misleading - VitalLaw.com
Huge proposed Memphis project downsizes by 500 jobs - The Business Journals
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Are Margin Pressures Shaping Charles River’s (CRL) Competitive Position Amid Stabilizing Revenue Guidance? - simplywall.st
Is Charles River Laboratories International Inc. exposed to currency risksPortfolio Gains Summary & Real-Time Volume Trigger Notifications - sundaytimes.kr
How Charles River Laboratories International Inc. stock reacts to Fed policy changesQuarterly Growth Report & Verified Swing Trading Watchlists - beatles.ru
Day 5 of Gains Streak for Charles River Laboratories International Stock with 5.3% Return (vs. -15% YTD) [8/15/2025] - Trefis
Charles River Laboratories International Inc. Stock Recovery Path — Analyst Breakdown2025 Market Sentiment & AI Enhanced Execution Alerts - sundaytimes.kr
Profitable Stocks to Watch: Dole, Charles River Laboratories, and LegalZoom - AInvest
Charles River Laboratories International Inc. Recovery Linked to Earnings Surprise2025 Analyst Calls & Real-Time Market Sentiment Alerts - sundaytimes.kr
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionJuly 2025 Technicals & Weekly High Conviction Trade Ideas - sisa-n.com
What is Charles River Laboratories International Inc. s 5 year growth outlookJuly 2025 Final Week & Accurate Intraday Trading Signals - sundaytimes.kr
Custom Dashboard Highlights Charles River Laboratories International Inc. Price MomentumEarnings Recap Summary & Technical Entry and Exit Tips - 선데이타임즈
5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call - Yahoo Finance
Do Charles River (CRL) Earnings Trends Reveal Shifting Priorities in Its Advanced Therapeutics Ambitions? - simplywall.st
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Labs: Buy Rating and $179 Price Target Amidst Stability and Value Creation Potential - AInvest
Charles River Laboratories Q2 2025 Earnings Call Transcript Summary - AInvest
Charles River Laboratories International Inc's Q2 2025 Financials and Strategic Direction: A SWOT Analysis - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Laboratories Q2 2025 Earnings Call Transcript Review - AInvest
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):